Skip navigation
FACT
Focus on Alternative and Complementary Therapies

The effects of homoeopathic therapy on health-related quality of life

Becker-Witt C1, Lüdtke R2, Weber K1, Willich SN1
1Institute of Social Medicine, Epidemiology and Health Economics, Charité Hospital, Humboldt-University of Berlin, Berlin, D-10098, Germany
2Karl und Veronica Carstens Foundation, Essen, Germany

Objective

To describe the range of diagnoses seen in homoeopathic practices, and to evaluate long-term changes in quality of life (QoL) among patients receiving homoeopathic treatment.

Materials and methods

A prospective cohort study of consecutively recruited adults presenting for the first time at one of 102 primary homoeopathic care centers in Germany and Switzerland. Ther QoL measurements (SF-36) were made at baseline, 3, 12, and 24 months. Statistical analysis of data used general linear repeated measurement models.

Results

Among a total of 2851 patients (29.3% male, 42.5 ± 10.0 years; 70.7% female, 39.9 ± 12.4 years), 99% suffered from a chronic illness with a median disease duration of 10.3 ± 9.8 years. At baseline, QoL was lower on the Mental Component Scale (MCS) than on the Physical Component Scale (PCS) (MCS –1.51 and PCS –0.37 standard deviations below the mean of the general population). Across different diagnoses, improvements on the PCS were estimated to be 0.25 [95% confidence interval (CI) 0.19–0.31] standard deviations at 3 months, 0.36 (95% CI 0.30–0.42) and 0.40 (95% CI 0.34–0.47) at 24 months. The MCS changes were greater: 0.44 (95% CI 0.38–0.50) standard deviations at 3 months, 0.50 (95% CI 0.44–0.56) at 12 months and 0.56 (95% CI 0.50–0.62) at 24 months.

Conclusion

Almost all homoeopathically treated patients had been suffering from a chronic illness and were evidently searching for complementary treatment, but not an alternative to conventional medical care. Their QoL substantially improved primarily within the first few months of treatment and remained at this higher level. The results cannot be attributed to regression to the mean or to selective dropouts.

Top | Next: Adjuvant standardised mistletoe extract in early stage breast carcinoma – a multicentre comparative retrolective epidemiological cohort study»
© Pharmaceutical Press 2007
Accessibility | Terms and Conditions